PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsAOP Health
AOP Health
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
BesremiRopeginterferon alfa-2b2019-02-15
Polycythemia vera
Sugammadex amomedSugammadex2023-01-102026
Neuromuscular blockade
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Ropeginterferon alfa-2b
chronic hepatitis
,
healthy volunteers/patients
,
t-cell lymphoma cutaneous
,
neoplasms
,
hepatitis
,
hepatitis a
,
hepatitis d
,
coinfection
,
hepatocellular carcinoma
,
liver neoplasms
,
chronic hepatitis b
,
hepatitis c
,
chronic hepatitis c
,
essential thrombocythemia
,
thrombocytosis
,
infections
,
communicable diseases
,
primary myelofibrosis
,
polycythemia vera
,
polycythemia
,
myeloproliferative disorders
,
hepatitis b
,
herpesviridae infections
Landiolol
healthy volunteers/patients
,
pharmacokinetics
Benzocaine
respiratory distress syndrome
,
acute lung injury
,
newborn respiratory distress syndrome
,
syndrome
Tezosentan
pulmonary hypertension
,
pulmonary arterial hypertension
,
hypertension
,
familial primary pulmonary hypertension
,
congenital heart defects
,
heart diseases
,
eisenmenger complex
Alfacalcidol
dermatomyositis
,
ulcerative colitis
,
colitis
,
ulcer
,
hyperparathyroidism
,
secondary hyperparathyroidism
,
neoplasm metastasis
,
chronic renal insufficiency
,
left ventricular hypertrophy
,
kidney diseases
,
cardiomegaly
,
hypertrophy
Albinterferon alfa-2b
kidney neoplasms
,
aids-related opportunistic infections
,
leukemia
,
neoplasms
,
renal cell carcinoma
,
myeloid leukemia
,
communicable diseases
,
hiv
,
cutaneous malignant melanoma
,
brain neoplasms
,
gastrointestinal stromal tumors
,
cholangiocarcinoma
,
primary myelofibrosis
,
liver diseases
,
anemia
,
hypoxia
,
hereditary hemorrhagic telangiectasia
,
telangiectasis
,
pancreatic neoplasms
,
kaposi sarcoma
,
experimental liver cirrhosis
,
melanoma
,
bcr-abl positive chronic myelogenous leukemia
,
acquired immunodeficiency syndrome
,
coinfection
,
carcinoma
,
recurrence
,
menopause
,
neoadjuvant therapy
,
hepatocellular carcinoma
,
liver neoplasms
,
chronic hepatitis d
,
hepatitis d
,
liver transplantation
,
depression
,
depressive disorder
,
drug-related side effects and adverse reactions
,
neoplasm metastasis
,
essential thrombocythemia
,
hepatitis c
,
hepatitis
,
hepatitis a
,
chronic hepatitis c
,
chronic hepatitis
,
hiv infections
,
liver cirrhosis
,
fibrosis
,
hepatitis b
,
chronic hepatitis b
,
infections
,
hepacivirus
,
insulin resistance
,
chronic kidney failure
,
kidney diseases
,
homozygote
,
body weight
,
substance-related disorders
,
intravenous substance abuse
,
non-hodgkin lymphoma
,
lymphoma
,
follicular lymphoma
LANCOVUTIDE
fibrosis
,
cystic fibrosis
Nepidermin
crohn disease
,
rheumatoid arthritis
,
arthritis
,
systemic lupus erythematosus
Retinol
ulcerative colitis
,
crohn disease
,
colitis
,
ulcer
,
psoriasis
,
healthy volunteers/patients
,
rheumatoid arthritis
,
arthritis
,
atrial fibrillation
,
venous thromboembolism
,
venous thrombosis
,
pulmonary embolism
,
non-small-cell lung carcinoma
,
thromboembolism
,
percutaneous coronary intervention
,
cardiac arrhythmias
,
stroke
,
transient ischemic attack
,
transcatheter aortic valve replacement
,
acute coronary syndrome
,
thrombosis
,
embolism
,
intracranial hemorrhages
,
gastrointestinal hemorrhage
Ldla202
healthy volunteers/patients
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use